KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other financing activities (2016 - 2025)

Vertex Pharmaceuticals has reported Other financing activities over the past 14 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Other financing activities at $1.1 million for Q4 2025, up 22.22% from a year ago — trailing twelve months through Dec 2025 was $3.7 million (down 40.32% YoY), and the annual figure for FY2025 was $3.7 million, down 40.32%.
  • Other financing activities for Q4 2025 was $1.1 million at Vertex Pharmaceuticals, roughly flat from $1.1 million in the prior quarter.
  • Over the last five years, Other financing activities for VRTX hit a ceiling of $3.5 million in Q1 2024 and a floor of -$1.5 million in Q4 2023.
  • Median Other financing activities over the past 5 years was $1.1 million (2022), compared with a mean of $1.0 million.
  • Biggest five-year swings in Other financing activities: skyrocketed 1739.08% in 2021 and later plummeted 236.36% in 2023.
  • Vertex Pharmaceuticals' Other financing activities stood at $1.4 million in 2021, then decreased by 21.43% to $1.1 million in 2022, then plummeted by 236.36% to -$1.5 million in 2023, then soared by 160.0% to $900000.0 in 2024, then increased by 22.22% to $1.1 million in 2025.
  • The last three reported values for Other financing activities were $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $700000.0 (Q2 2025) per Business Quant data.